

PRESS RELEASE

Gradientech Partners with ELTA 90 MGR for Greece

Uppsala, Sweden, January 26, 2026. **The diagnostics company Gradientech today announces that it has entered into an exclusive distribution agreement with ELTA 90 MGR for the commercialisation of the QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST) in Greece.**

The agreement marks another important step in Gradientech's European expansion strategy and strengthens the company's presence in Southern Europe. Through this partnership, QuickMIC® will be made available to Greek hospitals seeking faster, actionable AST results to support timely antibiotic decision-making in routine clinical practice.

ELTA 90 MGR, part of the ELTA 90 Group, is a well-established Greek distributor of advanced biomedical and clinical diagnostic solutions, with strong expertise in clinical microbiology and long-standing relationships across the hospital market.

"ELTA 90 MGR is proud to partner with Gradientech and bring the QuickMIC® system to the Greek market," says Vasilis Koutsokostas, General Manager at ELTA 90 MGR. "By combining ELTA's strong local presence and deep clinical microbiology expertise with Gradientech's innovative, same-shift AST technology, we aim to support clinicians with faster and more precise susceptibility data. This is particularly important in Greece, which continues to face one of the highest antimicrobial resistance rates in Europe, especially in severe infections such as sepsis."

"Entering into this exclusive agreement with ELTA 90 MGR represents a strategically important milestone for Gradientech," says AnnaLotta Schiller, Chief Commercial Officer at Gradientech. "ELTA 90 MGR's strong expertise in clinical diagnostics, established market presence, and strong customer access provide an excellent platform to accelerate adoption of QuickMIC® in Greece."

QuickMIC® and its Gram-negative panel are CE marked and commercially available in Europe. QuickMIC is classified as a Breakthrough Device by the U.S. Food and Drug Administration and available for Investigational Use Only in the U.S., but not 510(k) cleared.

For further information, please contact:

Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se

About Gradientech

Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our innovative diagnostic solutions aim to save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit [gradientech.se](https://www.gradientech.se) for more information.

About ELTA 90 MGR

ELTA 90 MGR is a trusted distributor of high-quality biomedical equipment, dedicated to advancing healthcare through innovative solutions. Partnering with leading manufacturers, the company provides state-of-the-art

diagnostic and medical technologies that help healthcare professionals deliver exceptional patient care. With a strong commitment to excellence, ELTA 90 MGR combines premium products with expert guidance and support, striving to be more than a supplier—an active partner in improving healthcare outcomes. Visit elta90mgr.gr for more information.